Organization | Hellenic Society of Hematology

Hellenic Society of Hematology Report issue

Academic/Hospital Phase 2

Founded: Athens Greece (1961)

Organization Overview

First Clinical Trial

2018

NCT03450057

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

Hellenic Society of Hematology

Active Ingredients

Drugs in Phase 2 Trials (13)

acetaminophen (tylenol) (1 trial)

belantamab mafodotin (TECVAYLI) (4 trials)

bortezomib (velcade) (1 trial)

cyclophosphamide (cytoxan) (1 trial)

daratumumab (darzalex) (5 trials)

dexamethasone (6 trials)

diphenhydramine (benadryl) (1 trial)

Isatuximab (Sarclisa) (2 trials)

ixazomib (ninlaro) (1 trial)

lenalidomide (revlimid) (3 trials)

nirogacestat (Ogsiveo) (1 trial)

pomalidomide (pomalyst) (2 trials)

ranitidine (zantac) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Multiple Myeloma (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 9
# of Trial APIs: 13